Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

Detalhes bibliográficos
Main Authors:	Baek, R, Kasperzyk, J, Platt, F, Seyfried, T
Formato:	Conference item
Publicado em:	2005

Registos relacionados

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Por: Baek, R, et al.
Publicado em: (2008)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
Por: Baek, R, et al.
Publicado em: (2004)

Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
Por: Kasperzyk, J, et al.
Publicado em: (2002)

Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
Por: J.L. Kasperzyk, et al.
Publicado em: (2005-04-01)

"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
Por: Kasperzyk, J, et al.
Publicado em: (2005)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Por: Kasperzyk, J, et al.
Publicado em: (2004)

Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
Por: Kasperzyk, J, et al.
Publicado em: (2005)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
Por: Kasperzyk, J, et al.
Publicado em: (2004)

Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice
Por: Kasperzyk, J, et al.
Publicado em: (2003)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Por: Denny, C, et al.
Publicado em: (2010)

Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
Por: Seyfried, T, et al.
Publicado em: (2003)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
Por: Lachmann, R, et al.
Publicado em: (2006)

Influence of ganglioside GM3 and high density lipoprotein on the cohesion of mouse brain tumor cells.
Por: H Bai, et al.
Publicado em: (1997-01-01)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Por: Andersson, U, et al.
Publicado em: (2004)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
Por: Ulrika Andersson, et al.
Publicado em: (2004-08-01)

Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity
Por: Yi-Chen Hsieh, et al.
Publicado em: (2022-09-01)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Por: Jeyakumar, M, et al.
Publicado em: (2001)

Serum gangliosides in mice with metastatic and non-metastatic brain tumors.
Por: M Cotterchio, et al.
Publicado em: (1994-01-01)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
Por: Ranes, M, et al.
Publicado em: (2001)

Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review
Por: Wenchao Zhang, et al.
Publicado em: (2019-06-01)

Thematic Review Series: Sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a*
Por: Purna Mukherjee, et al.
Publicado em: (2008-05-01)

GM1 and GM2 gangliosides: recent developments
Por: Bisel Blaine, et al.
Publicado em: (2014-03-01)

GM1 ganglioside-independent intoxication by Cholera toxin
Por: Cervin, J, et al.
Publicado em: (2018)

GM1 ganglioside-independent intoxication by Cholera toxin.
Por: Jakob Cervin, et al.
Publicado em: (2018-02-01)

The relationship between depletion of brain GM1 ganglioside and Parkinson's disease
Por: Sandro Sonnino
Publicado em: (2023-09-01)

Generalized accumulation of neutral glycosphingolipids with GM2 ganglioside accumulation in the brain
Por: Paul D. Snyder, Jr., et al.
Publicado em: (1972-01-01)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
Por: Pshezhetsky, A, et al.
Publicado em: (2017)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
Por: Pshezhetsky, A, et al.
Publicado em: (2017)

Isolation and characterization of ganglioside GM1b from normal human brain.
Por: T Ariga, et al.
Publicado em: (1987-03-01)

Effect of Golgi membrane phospholipid composition on the molecular species of GM3 gangliosides synthesized by rat liver sialyltransferase.
Por: H Kadowaki, et al.
Publicado em: (1994-11-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
Por: Huebecker, M, et al.
Publicado em: (2019)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
Por: te Vruchte, D, et al.
Publicado em: (2010)

CREB5 hypermethylation involved in the ganglioside GM1 therapy of Parkinson’s disease
Por: Rui Wang, et al.
Publicado em: (2023-05-01)

Enhanced Susceptibility to Chemoconvulsant-Induced Seizures in Ganglioside GM3 Synthase Knockout Mice
Por: Fu-Lei Tang, et al.
Publicado em: (2020-07-01)

The Key Role of GM1 Ganglioside in Parkinson’s Disease
Por: Suman Chowdhury, et al.
Publicado em: (2022-01-01)

Preparation of radiolabeled GM2 and GA2 gangliosides.
Por: A Novak, et al.
Publicado em: (1979-07-01)

Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease
Por: Mylene Huebecker, et al.
Publicado em: (2019-11-01)

Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
Por: Maria L. Allende, et al.
Publicado em: (2023-12-01)

Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Por: Jay S Schneider, et al.
Publicado em: (2015-01-01)

Infantile Sandhoff's disease
Por: K Sass, et al.
Publicado em: (2009-08-01)